ライフサイエンスコーパス: sacubitril

1 a PKG-dependent mechanism by which valsartan/sacubitril, a combination drug recently approved for tre

2 a induced by neprilysin inhibitors, that is, sacubitril, are unclear, although a contribution of brad

3 or the treatment of heart failure: Valsartan/sacubitril (formerly known as LCZ696 and currently marke

4 lsartan and the neprilysin inhibitor prodrug sacubitril in a 1:1 ratio in a sodium supramolecular com

5 trials are evaluating the role of valsartan/sacubitril in the treatment of heart failure with preser

6 Sacubitril is an ethyl ester prodrug of LBQ657, the acti

7 Sacubitril is converted by esterases to LBQ657, which in

8 Heart Failure (PARADIGM-HF) trial, valsartan/sacubitril significantly reduced mortality and hospitali

9 w here the mechanisms of action of valsartan/sacubitril, the pharmacological properties of the drug,

10 Results of Base-Case Analysis: The sacubitril-valsartan group experienced 0.08 fewer heart

11 Limitation: The benefit of sacubitril-valsartan is based on a single clinical trial

12 Intervention: Treatment with sacubitril-valsartan or lisinopril.

13 Conclusion: Treatment with sacubitril-valsartan provides reasonable value in reduci

14 Background: Sacubitril-valsartan therapy reduces cardiovascular mort

15 Results of Sensitivity Analysis: Sacubitril-valsartan treatment was most sensitive to the

16 ctive: To evaluate the cost-effectiveness of sacubitril-valsartan versus angiotensin-converting enzym

17 insulin was 29% lower in patients receiving sacubitril/valsartan (114 [7%] patients) compared with p

18 ients randomly assigned to enalapril than to sacubitril/valsartan (3.1 vs 2.2 per 100 patient-years;

19 enalapril than to those randomly assigned to sacubitril/valsartan (3.3 vs 2.3 per 100 patient-years;

20 Heart Failure (PARADIGM-HF) trial, in which sacubitril/valsartan (LCZ696) reduced both death and HF

21 he angiotensin receptor neprilysin inhibitor sacubitril/valsartan (LCZ696) reduced cardiovascular mor

22 study sought to determine if treatment with sacubitril/valsartan (LCZ696) reduces rates of hospital

23 reatment with enalapril 10 mg twice daily or sacubitril/valsartan 97/103 mg twice daily (previously k

24 ricular EF (LVEF) </=40%] were randomized to sacubitril/valsartan 97/103 mg twice daily versus enalap

25 y outcomes and assessed the effectiveness of sacubitril/valsartan across the LVEF spectrum.

26 l in 31% versus 17% of patients treated with sacubitril/valsartan and enalapril, respectively.

27 included the wholesale acquisition cost for sacubitril/valsartan and enalapril.

28 ores demonstrated consistent improvements in sacubitril/valsartan compared with enalapril through 36

29 linical outcomes and on the effectiveness of sacubitril/valsartan compared with enalapril.

30 scores were better in patients treated with sacubitril/valsartan compared with those treated with en

31 e enalapril group and 0.26% (SD 1.25) in the sacubitril/valsartan group (between-group reduction 0.13

32 At 8 months, sacubitril/valsartan group noted improvements in both KC

33 oncentrations were persistently lower in the sacubitril/valsartan group than in the enalapril group o

34 ic therapy (0.77, 0.58-1.02, p=0.073) in the sacubitril/valsartan group.

35 d HFrEF enrolled in PARADIGM-HF who received sacubitril/valsartan had a greater long-term reduction i

36 Sacubitril/valsartan has been approved for use in heart

37 f MRAs for patients with HFrEF is reduced by sacubitril/valsartan in comparison with enalapril.

38 These findings demonstrate that sacubitril/valsartan leads to better HRQL in surviving p

39 These data suggest that sacubitril/valsartan might enhance glycaemic control in

40 who were randomly assigned to treatment with sacubitril/valsartan or enalapril.

41 on: ivabradine and another combination drug, sacubitril/valsartan or LCZ696.

42 The benefit of sacubitril/valsartan over enalapril was similar to the p

43 l Mortality and Morbidity in Heart Failure), sacubitril/valsartan reduced morbidity and mortality com

44 ed ejection fraction, whether treatment with sacubitril/valsartan reduced NT-proBNP below specific pa

45 The incremental costs and QALYs gained with sacubitril/valsartan treatment were estimated at $35512

46 Overall, the sacubitril/valsartan versus enalapril hazard ratio for t

47 We aimed to investigate the effect of sacubitril/valsartan versus enalapril on HbA1c and time

48 sions per 1000 patients with HF treated with sacubitril/valsartan vs enalapril over 30 years.

49 he angiotensin receptor neprilysin inhibitor sacubitril/valsartan was associated with a reduction in

50 The effect of sacubitril/valsartan was consistent across all subgroups

51 Sacubitril/valsartan was effective across the LVEF spect

52 Sacubitril/valsartan was effective at reducing cardiovas

53 he angiotensin receptor neprilysin inhibitor sacubitril/valsartan was more effective than the angiote

54 Treatment with sacubitril/valsartan was nearly twice as likely as enala

55 n fraction, the Markov model calculated that sacubitril/valsartan would increase life expectancy at a

56 Sensitivity analyses demonstrated sacubitril/valsartan would remain cost-effective vs enal

57 The benefit of LCZ696 (sacubitril/valsartan) compared with enalapril was consis

58 (NEP) inhibitor, and a component of LCZ696 (sacubitril/valsartan).

59 Sacubitril/valsartan, a combination angiotensin receptor

60 The benefit of sacubitril/valsartan, over an angiotensin-converting enz

61 Given improvements in mortality with sacubitril/valsartan, this analysis provides comprehensi

62 In sacubitril/valsartan-treated patients, median NT-proBNP

63 ly during treatment with enalapril than with sacubitril/valsartan.